Physician profile
Charles E Shipman
NPI 1508898198
$5,898.55
in general payments reported to CMS, 2019-2025
30 companies · $512 in 2025
The $512 reported for 2025 was more than what 84% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $869 · 2021: $925 · 2022: $851 · 2023: $1,030 · 2024: $796 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,360.85 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $962.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $722.31 | 2019-2023 | Xarelto |
| Amgen INC. | $303.67 | 2019-2025 | Evenity, Prolia, Prolia |
| Paratek Pharmaceuticals, INC. | $288.44 | 2022-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $266.78 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $243.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $227.57 | 2019-2022 | |
| Pfizer INC. | $217.14 | 2019-2024 | |
| Novo Nordisk INC | $152.13 | 2020-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $141.42 | 2019-2022 | |
| Ardelyx, INC. | $138.93 | 2024-2025 | Ibsrela |
| Abbvie INC. | $125.49 | 2021-2023 | Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.31 | 2019-2021 | |
| Exact Sciences Corporation | $109.53 | 2023-2024 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $92.84 | 2021 | |
| Antares Pharma, INC. | $84.10 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $70.15 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $52.32 | 2023-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $38.09 | 2021-2023 | Seglentis, Livalo |
| Lilly USA, LLC | $35.60 | 2019-2025 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $33.84 | 2024 | Voquezna |
| Halozyme INC | $18.72 | 2023 | |
| Corcept Therapeutics | $18.61 | 2024 | Korlym |
| Allergan, INC. | $16.11 | 2020 | |
| Horizon Therapeutics Plc | $13.73 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.58 | 2020 | |
| Eisai INC. | $13.07 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.30 | 2019 | |
| Esperion Therapeutics, INC. | $12.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Shipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.